Chief Executive Officer, Emmer Capital Partners Limited

Manishi Raychaudhuri

Chief Executive Officer

Emmer Capital Partners Limited

Emmer Capital Partners is an Asia Pacific focused financial advisory firm engaging in strategic financial asset allocation advice, bespoke thematic research and advising early-stage companies and connecting them to investors. Emmer Capital provides macro-economic and multi-asset investment strategy inputs to institutions, family offices, private wealth managers, private equity, and corporate boards directly and through independent research platforms. Emmer Capital also advises a wide range of startup companies on fund raising and business strategy. Emmer Capital's active engagement with the print and electronic media reaches a broad spectrum of investors across the globe.

Cross Asset Strategy

<ul>
<li>From July's recent peak of US$17.3bn, onshore investors' net Southbound buying declined to US$14.3 bn in August. Average daily turnover continued to climb, reaching an all-time high of US$19.8bn.</li>
<li>Buying in Tencent, Xiaomi and Alibaba re-commenced, after selling for 3-4 months. The semiconductor giants - SMIC and Hua Hong - are being bought as well. </li>
<li>Investors' long-standing preferences for e-commerce, food delivery, biotech and dividends continue. Meituan and Kuaishou continue to be bought, despite the recent losses. Akeso, XTALPI and Innovent occupy the biotech space.</li>
</ul>


From July's recent peak of US$17.3bn, onshore investors' net Southbound buying declined to US$14.3 bn in August. Average daily turnover continued to climb, reaching an all-time high of US$19.8bn.
Buying in Tencent, Xiaomi and Alibaba re-commenced, after selling for 3-4 months. The semiconductor giants - SMIC and Hua Hong - are being bought as well. 
Investors' long-standing preferences for e-commerce, food delivery, biotech and dividends continue. Meituan and Kuaishou continue to be bought, despite the recent losses. Akeso, XTALPI and Innovent occupy the biotech space.


Asian Equities: Southbound Monthly - Slowdown in August but Renewed Enthusiasm for Tech Superstars

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the monthly Hong Kong Connect flows with our data engine.</li>
<li>We tabulate the top stocks by inflows, outflows, and holding by mainland investors.</li>
<li>We highlight flows of Alibaba, Tencent, Meituan, China Life, HSTECH ETF.</li>
</ul>


We analyze the monthly Hong Kong Connect flows with our data engine.
We tabulate the top stocks by inflows, outflows, and holding by mainland investors.
We highlight flows of Alibaba, Tencent, Meituan, China Life, HSTECH ETF.


Hong Kong Connect Flows (August): $18bn Inflows

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Zylox-Tonbridge Medical Technology / Equity Bottom-Up

<ul>
<li>We strongly disagree with the valuation method of "P/R". which is calculated by dividing market value by R&amp;D expenses. It is still necessary to view the valuation system rationally.</li>
<li>Innovent surprisingly turned loss into profits for the first time in 25H1. Considering the future contribution of mazdutide and IBI363, valuation of Innovent may reach above RMB200 billion.</li>
<li>The logic of Zylox is import substitution. Based on strong fundamentals, if liquidity remains strong, reasonable P/E is 40-45x. Target share price is HK$25-29/share based on 2025 net profit.</li>
</ul>


We strongly disagree with the valuation method of "P/R". which is calculated by dividing market value by R&amp;D expenses. It is still necessary to view the valuation system rationally.
Innovent surprisingly turned loss into profits for the first time in 25H1. Considering the future contribution of mazdutide and IBI363, valuation of Innovent may reach above RMB200 billion.
The logic of Zylox is import substitution. Based on strong fundamentals, if liquidity remains strong, reasonable P/E is 40-45x. Target share price is HK$25-29/share based on 2025 net profit.


China Healthcare Weekly (Aug.31) - P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results

Equity Capital Markets

GenFleet Therapeutics / Equity Capital Markets

<ul>
<li>GenFleet, a China-based near-commercial stage biotech company, is looking to raise around USD 250 million via a Hong Kong listing. CITIC Securities is the sole sponsor.</li>
<li>In this note, we look at the company’s core products, GFH925 and GFH375.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


GenFleet, a China-based near-commercial stage biotech company, is looking to raise around USD 250 million via a Hong Kong listing. CITIC Securities is the sole sponsor.
In this note, we look at the company’s core products, GFH925 and GFH375.
We also look at the company’s pre-IPO investors and management team.


GenFleet Therapeutics (劲方医药) Pre-IPO: Leadership in KRAS G12D Target

Akeso Biopharma Inc / Equity Capital Markets

<ul>
<li>OS benefit has been observed in HARMONi-A study, which however is just a small part of the PD-1/VEGF commercial landscape. The main battlefield is still the head-to-head trial against Keytruda.</li>
<li>We think the current high valuation of Akeso has begun to price in the successful HARMONi-2 results to some extent, which however is not a done deal.</li>
<li>Investors may need to be cautious about this placement, especially when the founders of Akeso actually chose to reduce their positions. Market cooling down may not be far off.</li>
</ul>


OS benefit has been observed in HARMONi-A study, which however is just a small part of the PD-1/VEGF commercial landscape. The main battlefield is still the head-to-head trial against Keytruda.
We think the current high valuation of Akeso has begun to price in the successful HARMONi-2 results to some extent, which however is not a done deal.
Investors may need to be cautious about this placement, especially when the founders of Akeso actually chose to reduce their positions. Market cooling down may not be far off.


Akeso Biopharma (9926 HK) Placement - We Are Now at a Critical Point

China

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innovent Biologics Inc (1801 HK)

Asian Equities: Southbound Monthly - Slowdown in August but Renewed Enthusiasm for Tech Superstars

Southbound buying declined in Aug, but avg daily turnover hit an all-time high. Buying resumed in Tencent, Xiaomi, Alibaba & Hua Hong. Food...

Manishi Raychaudhuri

Hong Kong Connect Flows (August): $18bn Inflows

We estimate inflows into HK via southbound trade were $18bn in August, at four month high. We highlight inflows for Alibaba, Tencent, Meituan, and...

Ke Yan, CFA, FRM

China Healthcare Weekly (Aug.31) - P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results

The valuation method of "P/R" that is calculated by dividing market value by R&D expense is meaningless.Innovent turns profit, with valuation...

Xinyao (Criss) Wang

GenFleet Therapeutics (劲方医药) Pre-IPO: Leadership in KRAS G12D Target

China's GenFleet seeks to raise $250m through Hong Kong listing, with CITIC Securities as sole sponsor. We look at its core products, management...

Ke Yan, CFA, FRM

Akeso Biopharma (9926 HK) Placement - We Are Now at a Critical Point

Akeso's potential success in HARMONi-2 study may be already factored into high valuation. Investors need to be cautious about this placement,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Asian Equities: Southbound Monthly - Slowdown in August but Renewed Enthusiasm for Tech Superstars

Southbound buying declined in Aug, but avg daily turnover hit an all-time high. Buying resumed in Tencent, Xiaomi, Alibaba & Hua Hong. Food...

Manishi Raychaudhuri

Hong Kong Connect Flows (August): $18bn Inflows

We estimate inflows into HK via southbound trade were $18bn in August, at four month high. We highlight inflows for Alibaba, Tencent, Meituan, and...

Ke Yan, CFA, FRM

China Healthcare Weekly (Aug.31) - P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results

The valuation method of "P/R" that is calculated by dividing market value by R&D expense is meaningless.Innovent turns profit, with valuation...

Xinyao (Criss) Wang

GenFleet Therapeutics (劲方医药) Pre-IPO: Leadership in KRAS G12D Target

​China's GenFleet seeks to raise $250m through Hong Kong listing, with CITIC Securities as sole sponsor. We look at its core products, management...

Ke Yan, CFA, FRM

Akeso Biopharma (9926 HK) Placement - We Are Now at a Critical Point

​Akeso's potential success in HARMONi-2 study may be already factored into high valuation. Investors need to be cautious about this placement,...

Xinyao (Criss) Wang

China's GenFleet seeks to raise $250m through Hong Kong listing, with CITIC Securities as sole sponsor. We look at its core products, management...

Akeso's potential success in HARMONi-2 study may be already factored into high valuation. Investors need to be cautious about this placement,...